A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

• Drug: UK-453, 061
  
  UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
• Drug: UK-453, 061
  
  UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
• Drug: EFV +TVA
  
  Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.

• Experimental: UK- 453,061 Dose One
  
  UK 453,061 Dose One plus Truvada
  Intervention: Drug: UK-453, 061
• Experimental: UK-453,061 Dose Two
  
  UK 453,061 Dose Two plus Truvada
  Intervention: Drug: UK-453, 061
• Active Comparator: Efavirenz + Truvada
  
  Efavirenz + Truvada
  Intervention: Drug: EFV +TVA

Inclusion Criteria:

• Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
• HIV 1 RNA viral load of greater then 1,000 copies/mL
• Negative urine pregnancy test.

Exclusion Criteria:

• Suspected or documented active, untreated HIV-1 related opportunist infection or other condition requiring acute therapy at the time of randomization.
• Subjects with acute Hepatitis B and/or C within 30 days of randomization.
• Absolute CD4 count <200 cells/mm3.